Skip to content
Catalyst

yohimbineWhat was measured

Measured, with no finding

848 endpoints

Show what was measuredHide what was measured
  • diastolic blood pressure condition × time effect

    increases, p = 0.05

    As with systolic blood pressure, a condition × time (p = 0.05) and sex (p < 0.0001) effect was noted for diastolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure sex effect

    modulates, p = 0.0001

    As with systolic blood pressure, a condition × time (p = 0.05) and sex (p < 0.0001) effect was noted for diastolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Men | 74 ± 2 | 74 ± 2 | 74 ± 2 | 78 ± 2 | 71 ± 3 | 74 ± 3 | 72 ± 3

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Meltdown® | Women | 64 ± 2 | 68 ± 2 | 71 ± 2 | 71 ± 2 | 66 ± 2 | 69 ± 1 | 69 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Men | 69 ± 2 | 71 ± 2 | 69 ± 2 | 68 ± 2 | 67 ± 2 | 65 ± 2 | 67 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • diastolic blood pressure

    DBP (mmHg) Placebo | Women | 69 ± 2 | 68 ± 2 | 68 ± 2 | 66 ± 2 | 65 ± 2 | 61 ± 2 | 63 ± 2

    PMID 19656409 · one of two readings recorded this

  • epinephrine AUC response, Meltdown compared to placebo

    increases

    The mean EPI AUC response for Meltdown® compared to placebo was 96% for men and 91% for women

    PMID 19656409 · one of two readings recorded this

  • epinephrine AUC response, Meltdown compared to placebo

    increases

    The mean EPI AUC response for Meltdown® compared to placebo was 96% for men and 91% for women

    PMID 19656409 · one of two readings recorded this

  • epinephrine AUC sex × condition interaction

    no effect, p = 0.57

    When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)

    PMID 19656409 · one of two readings recorded this

  • epinephrine AUC sex effect

    no effect, p = 0.11

    a condition effect was noted for EPI (p = 0.01; Figure 2A), with no sex effect noted (p = 0.11)

    PMID 19656409 · one of two readings recorded this

  • epinephrine AUC

    increases, p = 0.01

    Greater epinephrine (367 ± 58 pg·mL-1·6 hr-1 vs. 183 ± 27 pg·mL-1·6 hr-1; p = 0.01)

    PMID 19656409 · one of two readings recorded this

  • epinephrine over time versus pre-ingestion

    increases, p = 0.05

    Values increased across time with Meltdown® and were higher at 1, 2, and 3 hours post ingestion compared to pre-ingestion (p < 0.05)

    PMID 19656409 · one of two readings recorded this

  • free fatty acids AUC response, Meltdown compared to placebo

    increases

    The mean FFA AUC response for Meltdown® compared to placebo was 21% for men and 35% for women

    PMID 19656409 · one of two readings recorded this

  • free fatty acids AUC response, Meltdown compared to placebo

    increases

    The mean FFA AUC response for Meltdown® compared to placebo was 21% for men and 35% for women

    PMID 19656409 · one of two readings recorded this

  • free fatty acids AUC sex × condition interaction

    no effect, p = 0.37

    When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)

    PMID 19656409 · one of two readings recorded this

  • free fatty acids AUC sex effect

    modulates, p = 0.05

    Both a condition (p = 0.05; Figure 3B) and sex (p = 0.05) effect was noted for FFA, with values higher for women compared to men

    PMID 19656409 · one of two readings recorded this

  • free fatty acids AUC

    increases, p = 0.05

    FFA (2.46 ± 0.64 mmol·L-1·6 hr-1 vs. 1.57 ± 0.42 mmol·L-1·6 hr-1; p = 0.05)

    PMID 19656409 · one of two readings recorded this

  • free fatty acids over time versus pre-ingestion

    increases, p = 0.05

    Values increased across time with Meltdown® and were higher at 1 and 3 hours post ingestion compared to pre-ingestion (p < 0.05)

    PMID 19656409 · one of two readings recorded this

  • glycerol AUC response, Meltdown compared to placebo

    increases

    The mean glycerol AUC response for Meltdown® compared to placebo was 25% for men and 42% for women

    PMID 19656409 · one of two readings recorded this

  • glycerol AUC response, Meltdown compared to placebo

    increases

    The mean glycerol AUC response for Meltdown® compared to placebo was 25% for men and 42% for women

    PMID 19656409 · one of two readings recorded this

  • glycerol AUC sex × condition interaction

    no effect, p = 0.39

    When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)

    PMID 19656409 · one of two readings recorded this

  • glycerol AUC sex effect

    modulates, p = 0.01

    Both a condition (p = 0.03; Figure 3A) and sex (p = 0.01) effect was noted for glycerol, with values higher for women compared to men

    PMID 19656409 · one of two readings recorded this

  • glycerol AUC

    increases, p = 0.03

    Greater glycerol (79 ± 8 μg·mL-1·6 hr-1 vs. 59 ± 6 μg·mL-1·6 hr-1; p = 0.03)

    PMID 19656409 · one of two readings recorded this

  • glycerol over time versus pre-ingestion

    increases, p = 0.05

    Values increased across time with Meltdown® and were higher at 1, 2, and 3 hours post ingestion compared to pre-ingestion (p < 0.05)

    PMID 19656409 · one of two readings recorded this

  • heart rate condition effect

    increases, p = 0.01

    A condition effect was noted for heart rate (p = 0.01), with values higher with Meltdown® compared to placebo

    PMID 19656409 · one of two readings recorded this

  • heart rate (monitor), after ingestion of the Meltdown supplement vs placebo in a crossover; also plasma epinephrine, norepinephrine, glycerol, free fatty acids (ELISA/kits) AUC, kilocalorie expenditure by indirect calorimetry, blood pressure

    increases, heart rate higher with Meltdown than placebo, condition effect, p = 0.01, n = 20

    Not recorded as a finding: the intervention held more than the compound

    A condition effect was noted for heart rate (p = 0.01), with values higher with Meltdown® compared to placebo.

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Men | 54 ± 3 | 54 ± 3 | 62 ± 7 | 59 ± 4 | 63 ± 4 | 62 ± 3 | 60 ± 2

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Meltdown® | Women | 61 ± 4 | 56 ± 3 | 61 ± 4 | 61 ± 4 | 61 ± 3 | 65 ± 6 | 59 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Men | 56 ± 4 | 53 ± 3 | 53 ± 3 | 51 ± 3 | 60 ± 2 | 57 ± 2 | 54 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • heart rate

    HR (bpm) Placebo | Women | 62 ± 4 | 57 ± 3 | 56 ± 4 | 57 ± 4 | 59 ± 4 | 59 ± 4 | 56 ± 3

    PMID 19656409 · one of two readings recorded this

  • kilocalorie AUC response, Meltdown compared to placebo

    increases

    The mean kilocalorie AUC response for Meltdown® compared to placebo was 19% for men and 13% for women

    PMID 19656409 · one of two readings recorded this

  • kilocalorie AUC response, Meltdown compared to placebo

    increases

    The mean kilocalorie AUC response for Meltdown® compared to placebo was 19% for men and 13% for women

    PMID 19656409 · one of two readings recorded this

  • kilocalorie AUC sex × condition interaction

    no effect, p = 0.27

    When considering the AUC analysis, no sex × condition interactions were noted for kilocalories (p = 0.27) or RER (p = 0.87)

    PMID 19656409 · one of two readings recorded this

  • kilocalorie expenditure AUC sex effect

    modulates, p = 0.001

    both a condition (p = 0.02; Figure 4A) and sex (p < 0.001) effect was noted for kilocalorie expenditure, with values higher for men compared to women

    PMID 19656409 · one of two readings recorded this

  • kilocalorie expenditure AUC

    increases, p = 0.02

    Greater kilocalories (439 ± 26 kcal·6 hrs-1 vs. 380 ± 14 kcal·6 hrs-1; p = 0.02)

    PMID 19656409 · one of two readings recorded this

  • kilocalorie expenditure over time versus pre-ingestion

    increases, p = 0.05

    Values increased across time with Meltdown® and were higher at 1, 2, 3, 4, and 5 hours post ingestion compared to pre-ingestion (p < 0.05)

    PMID 19656409 · one of two readings recorded this

  • meal replacement bar consumed

    Female subjects consumed a mean of 62 grams of the 112 gram bar, while male subjects consumed a mean of 102 grams of the 112 gram bar

    PMID 19656409 · one of two readings recorded this

  • meal replacement bar consumed

    Female subjects consumed a mean of 62 grams of the 112 gram bar, while male subjects consumed a mean of 102 grams of the 112 gram bar

    PMID 19656409 · one of two readings recorded this

  • norepinephrine AUC response, Meltdown compared to placebo

    increases

    The mean NE AUC response for Meltdown® compared to placebo was 44% for men and 42% for women

    PMID 19656409 · one of two readings recorded this

  • norepinephrine AUC response, Meltdown compared to placebo

    increases

    The mean NE AUC response for Meltdown® compared to placebo was 44% for men and 42% for women

    PMID 19656409 · one of two readings recorded this

  • norepinephrine AUC sex × condition interaction

    no effect, p = 0.58

    When considering the AUC analysis, no sex × condition interactions were noted for EPI (p = 0.57), NE (p = 0.58), glycerol (p = 0.39), or FFA (p = 0.37)

    PMID 19656409 · one of two readings recorded this

  • norepinephrine AUC sex effect

    modulates, p = 0.01

    Both a condition (p = 0.02; Figure 2B) and sex (p = 0.01) effect was noted for NE, with values higher for men compared to women

    PMID 19656409 · one of two readings recorded this

  • norepinephrine AUC

    increases, p = 0.02

    norepinephrine (2345 ± 205 pg·mL-1·6 hr-1 vs. 1659 ± 184 pg·mL-1·6 hr-1; p = 0.02)

    PMID 19656409 · one of two readings recorded this

  • norepinephrine over time versus pre-ingestion

    increases, p = 0.05

    Values increased across time with Meltdown® and were higher at 1 and 3 hours post ingestion compared to pre-ingestion (p < 0.05)

    PMID 19656409 · one of two readings recorded this

  • respiratory exchange ratio AUC condition effect

    no effect, p = 0.39

    Neither a condition (p = 0.39; Figure 4B) nor a sex (p < 0.53) effect was noted for RER

    PMID 19656409 · one of two readings recorded this

  • respiratory exchange ratio AUC sex × condition interaction

    no effect, p = 0.87

    When considering the AUC analysis, no sex × condition interactions were noted for kilocalories (p = 0.27) or RER (p = 0.87)

    PMID 19656409 · one of two readings recorded this

  • respiratory exchange ratio AUC sex effect

    no effect, p = 0.53

    Neither a condition (p = 0.39; Figure 4B) nor a sex (p < 0.53) effect was noted for RER

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure condition × time effect

    increases, p = 0.03

    A condition × time (p = 0.03) and sex (p < 0.0001) effect was noted for systolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure sex effect

    modulates, p = 0.0001

    A condition × time (p = 0.03) and sex (p < 0.0001) effect was noted for systolic blood pressure, with values higher with Meltdown® across time, and higher for men compared to women

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Men | 118 ± 2 | 128 ± 3 | 131 ± 5 | 132 ± 4 | 131 ± 3 | 128 ± 3 | 126 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Meltdown® | Women | 104 ± 3 | 110 ± 2 | 114 ± 3 | 116 ± 3 | 112 ± 3 | 109 ± 2 | 109 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Men | 117 ± 3 | 117 ± 4 | 115 ± 2 | 116 ± 3 | 123 ± 2 | 117 ± 2 | 117 ± 3

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • systolic blood pressure

    SBP (mmHg) Placebo | Women | 104 ± 2 | 103 ± 2 | 107 ± 3 | 105 ± 2 | 107 ± 2 | 102 ± 2 | 104 ± 2

    PMID 19656409 · one of two readings recorded this

  • water intake

    water was allowed ad libitum, and was measured and matched for both days of testing (mean intake for women = 1921 mL; mean intake for men = 2163 mL)

    PMID 19656409 · one of two readings recorded this

  • water intake

    water was allowed ad libitum, and was measured and matched for both days of testing (mean intake for women = 1921 mL; mean intake for men = 2163 mL)

    PMID 19656409 · one of two readings recorded this

  • change in seated diastolic blood pressure

    increases, p = 0.011

    Seated systolic and diastolic blood pressure increased significantly during yohimbine as compared to placebo (18±5.1/11±2.4 versus −1±4.2/1±2.7, P=0.007, P=0.011, respectively)

    PMID 20837887 · one of two readings recorded this

  • change in seated systolic blood pressure

    increases, p = 0.007

    Seated systolic and diastolic blood pressure increased significantly during yohimbine as compared to placebo (18±5.1/11±2.4 versus −1±4.2/1±2.7, P=0.007, P=0.011, respectively)

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure from baseline 60 minutes after a single yohimbine 5.4 mg dose vs placebo, Dinamap automated brachial cuff, patients with severe autonomic failure (primary endpoint); also seated systolic/diastolic BP change and orthostatic symptom score

    increases, standing ΔDBP 11±3 mm Hg, 95% CI 6 to 16, yohimbine vs placebo, n = 31

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    For our primary endpoint, we found that only yohimbine significantly increased standing diastolic blood pressure from baseline at 60 minutes after drug administration compared with placebo (ΔDBP 11±3 mm Hg 95%CI: 6 to 16, P <0.001, significant using Bonferroni correction 0.05/3 for 3 comparisons).

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure

    no effect, p = 0.823

    We did not find a significant increase in standing DBP from baseline with pyridostigmine (ΔDBP 0.6±3 mm Hg 95%CI: −5 to 5, P =0.823)

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure

    increases, p = 0.001

    only yohimbine significantly increased standing diastolic blood pressure from baseline at 60 minutes after drug administration compared with placebo (ΔDBP 11±3 mm Hg 95%CI: 6 to 16, P <0.001

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure

    increases, p = 0.001

    There was a significantly increased in standing DBP with yohimbine compared with pyridostigmine (ΔDBP 9±3 mm Hg 95%CI: 4 to 15, P=0.001

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure

    increases, p = 0.006

    In our exploratory analyses with sixteen patients, the combination of pyridostigmine and yohimbine increased significantly standing diastolic blood pressure from baseline compared with placebo (ΔDBP 12±4 mm Hg 95%CI: 4 to 19, P=0.006)

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure

    increases, p = 0.003

    and pyridostigmine alone (ΔDBP 11±3 mm Hg 95%CI: 4 to 17, P=0.003)

    PMID 20837887 · one of two readings recorded this

  • change in standing diastolic blood pressure

    no effect, p = 0.504

    However the combination of pyridostigmine and yohimbine did not significantly increased standing diastolic blood pressure compared with yohimbine alone (ΔDBP 3±4 mm Hg 95%CI: −6 to 12, P=0.504)

    PMID 20837887 · one of two readings recorded this

  • decrease in diastolic blood pressure on standing

    decreases

    All subjects had a substantial decrease in systolic and diastolic blood pressure upon standing (−67±6/−33±4 mmHg) without an adequate compensatory heart rate increase (16±2 bpm)

    PMID 20837887 · one of two readings recorded this

  • decrease in systolic blood pressure on standing

    decreases

    All subjects had a substantial decrease in systolic and diastolic blood pressure upon standing (−67±6/−33±4 mmHg) without an adequate compensatory heart rate increase (16±2 bpm)

    PMID 20837887 · one of two readings recorded this

  • heart rate increase on standing

    increases

    All subjects had a substantial decrease in systolic and diastolic blood pressure upon standing (−67±6/−33±4 mmHg) without an adequate compensatory heart rate increase (16±2 bpm)

    PMID 20837887 · one of two readings recorded this

  • pre-syncopal symptoms

    no effect

    Neither pyridostigmine nor placebo experienced a significant improvement in pre-syncopal symptoms

    PMID 20837887 · one of two readings recorded this

  • pre-syncopal symptoms

    no effect

    Neither pyridostigmine nor placebo experienced a significant improvement in pre-syncopal symptoms

    PMID 20837887 · one of two readings recorded this

  • pre-syncopal symptoms

    decreases, p = 0.006

    the magnitude of pre-syncopal symptoms significantly improved after yohimbine alone (p=0.006)

    PMID 20837887 · one of two readings recorded this

  • primary: change in standing diastolic blood pressure 60 minutes after drug from baseline; secondary: change in seated systolic and diastolic blood pressure 1 hour after yohimbine 5.4 mg against placebo, automated brachial cuff (Dinamap) every 5 minutes, patients with severe autonomic failure

    increases, seated SBP/DBP change 18±5.1/11±2.4 on yohimbine versus -1±4.2/1±2.7 on placebo, p = 0.007

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    Seated systolic and diastolic blood pressure increased significantly during yohimbine as compared to placebo (18±5.1/11±2.4 versus −1±4.2/1±2.7, P=0.007, P=0.011, respectively).

    PMID 20837887 · one of two readings recorded this

  • seated blood pressure

    no effect

    As reported previously, pyridostigmine did not increase seated blood pressure significantly

    PMID 20837887 · one of two readings recorded this

  • seated blood pressure

    no effect

    No significant differences in the effect of pyridostigmine between patients with central versus those with peripheral autonomic failure were found

    PMID 20837887 · one of two readings recorded this

  • seated blood pressure

    increases

    Patients with central autonomic failure had statistically significant increase in seated blood pressure with yohimbine as compared to those with peripheral autonomic failure

    PMID 20837887 · one of two readings recorded this

  • standing diastolic blood pressure at baseline (carry-over check)

    no effect

    We found no differences in the standing diastolic blood pressure at baseline indicating that there was no carry-over effect

    PMID 20837887 · one of two readings recorded this

  • ACTH response

    increases

    Both challenges produced robust ACTH, cortisol and prolactin responses

    PMID 21289601 · one of two readings recorded this

  • alcohol craving ratings after a yohimbine challenge against a saline infusion in treatment-seeking alcohol-dependent inpatients; also anxiety ratings and ACTH, cortisol and prolactin responses; abstract only, instruments not named

    increases, craving modestly but significantly higher after yohimbine than after saline; no statistic in the abstract

    Not recorded as a finding: this platform holds no node for the endpoint

    Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion.

    PMID 21289601 · one of two readings recorded this

  • alcohol craving ratings after a yohimbine infusion challenge vs saline infusion, in treatment-seeking alcohol-dependent inpatients (also anxiety ratings, ACTH, cortisol, prolactin responses)

    increases, cravings modestly but significantly higher after yohimbine than saline, n = 25

    Not recorded as a finding: this platform holds no node for the endpoint

    Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion.

    PMID 21289601 · one of two readings recorded this

  • alcohol craving

    increases

    Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion

    PMID 21289601 · one of two readings recorded this

  • alcohol craving

    increases

    Cravings were modestly, but significantly higher following both yohimbine and mCPP challenge compared with saline infusion

    PMID 21289601 · one of two readings recorded this

  • anxiety ratings

    increases

    The mCPP, but not yohimbine significantly increased anxiety ratings

    PMID 21289601 · one of two readings recorded this

  • anxiety ratings

    no effect

    The mCPP, but not yohimbine significantly increased anxiety ratings

    PMID 21289601 · one of two readings recorded this

  • challenge-induced alcohol craving

    no effect

    Acamprosate administration did not influence craving

    PMID 21289601 · one of two readings recorded this

  • correlation between craving and alcoholism severity

    increases

    There was a significant correlation between craving and the degree of alcoholism severity

    PMID 21289601 · one of two readings recorded this

  • cortisol response

    increases

    Both challenges produced robust ACTH, cortisol and prolactin responses

    PMID 21289601 · one of two readings recorded this

  • prolactin response

    increases

    Both challenges produced robust ACTH, cortisol and prolactin responses

    PMID 21289601 · one of two readings recorded this

  • extinction of fear memory

    decreases

    The excessive release of noradrenaline during memory formation not only delayed the process of extinction 48 h later, but also triggered broader fear generalization

    PMID 22169947 · one of two readings recorded this

  • fear-arousing aspects of the noradrenergic-strengthened memory

    decreases

    Yet, the β-adrenergic receptor blocker during reconsolidation selectively 'neutralized' the fear-arousing aspects of the noradrenergic-strengthened memory and undermined the generalization of fear

    PMID 22169947 · one of two readings recorded this

  • fear generalization

    increases

    The excessive release of noradrenaline during memory formation not only delayed the process of extinction 48 h later, but also triggered broader fear generalization

    PMID 22169947 · one of two readings recorded this

  • fear generalization

    decreases

    Yet, the β-adrenergic receptor blocker during reconsolidation selectively 'neutralized' the fear-arousing aspects of the noradrenergic-strengthened memory and undermined the generalization of fear

    PMID 22169947 · one of two readings recorded this

  • fear responding

    decreases

    We observed a similar reduction in fear responding when propranolol HCl was administered after reactivation of the memory

    PMID 22169947 · one of two readings recorded this

  • change in heart rate

    no effect, p = 0.05, n = 17

    SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)

    PMID 22311903 · one of two readings recorded this

  • change in heart rate

    no effect, p = 0.05, n = 17

    SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)

    PMID 22311903 · one of two readings recorded this

  • change in heart rate

    no effect, p = 0.05, n = 17

    SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)

    PMID 22311903 · one of two readings recorded this

  • change in heart rate

    no effect, p = 0.05, n = 17

    SBP changes were not accompanied by significant changes from baseline in heart rate (placebo 1±6 bpm, yohimbine −1±5 bpm, atomoxetine 0±6 bpm and the combination 0±7 bpm; all comparisons P >0.05)

    PMID 22311903 · one of two readings recorded this

  • change in seated SBP

    unclear, n = 17

    The change from baseline in seated SBP produced by placebo (4±17 mmHg) was similar to that of yohimbine (7±17 mmHg) and atomoxetine (5±19 mmHg)

    PMID 22311903 · one of two readings recorded this

  • change in seated SBP

    unclear, n = 17

    The change from baseline in seated SBP produced by placebo (4±17 mmHg) was similar to that of yohimbine (7±17 mmHg) and atomoxetine (5±19 mmHg)

    PMID 22311903 · one of two readings recorded this

  • change in seated SBP

    increases, n = 17

    One hour after drug administration, the maximal increase in seated SBP was seen with the combination (31±33 mmHg [range −24 to 112 mmHg], 95% CI: 14 to 48 mmHg; Figure 1A and 1B), with an average SBP of 129±38 mmHg

    PMID 22311903 · one of two readings recorded this

  • change in seated SBP

    unclear, n = 17

    The change from baseline in seated SBP produced by placebo (4±17 mmHg) was similar to that of yohimbine (7±17 mmHg) and atomoxetine (5±19 mmHg)

    PMID 22311903 · one of two readings recorded this

  • decrease in SBP on standing

    decreases, n = 17

    On standing, all patients had a pronounced decrease in SBP (−69±29 mmHg) without an adequate compensatory heart rate increase (15±13 bpm)

    PMID 22311903 · one of two readings recorded this

  • heart rate increase on standing

    increases, n = 17

    On standing, all patients had a pronounced decrease in SBP (−69±29 mmHg) without an adequate compensatory heart rate increase (15±13 bpm)

    PMID 22311903 · one of two readings recorded this

  • increase in 1 minute standing SBP

    unclear, n = 12

    Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg

    PMID 22311903 · one of two readings recorded this

  • increase in 1 minute standing SBP

    unclear, n = 12

    Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg

    PMID 22311903 · one of two readings recorded this

  • increase in 1 minute standing SBP

    increases, n = 12

    Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg

    PMID 22311903 · one of two readings recorded this

  • increase in 1 minute standing SBP

    unclear, n = 12

    Compared to pre-drug administration, the increase in 1 minute standing SBP produced by placebo was 1±23 mmHg, atomoxetine 8±16 mmHg, yohimbine 9±22 mmHg and the combination 28±29 mmHg

    PMID 22311903 · one of two readings recorded this

  • orthostatic decrease in SBP

    no effect, p = 0.19, n = 5

    Both groups had severe orthostatic hypotension (PAF −77±29 vs. PD −54±25; P=0.190)

    PMID 22311903 · one of two readings recorded this

  • orthostatic decrease in SBP

    no effect, p = 0.19, n = 12

    Both groups had severe orthostatic hypotension (PAF −77±29 vs. PD −54±25; P=0.190)

    PMID 22311903 · one of two readings recorded this

  • orthostatic tolerance (AUCSBP) versus sum of individual drug effects

    increases, p = 0.041, n = 12

    Moreover, the combination had a significantly higher AUCSBP compared with the sum of those during the two drugs alone (P=0.041)

    PMID 22311903 · one of two readings recorded this

  • orthostatic tolerance (AUCSBP)

    no effect, p = 0.05, n = 12

    whereas the AUCSBP after atomoxetine and yohimbine alone were not different from placebo (P>0.05)

    PMID 22311903 · one of two readings recorded this

  • orthostatic tolerance (AUCSBP)

    increases, p = 0.016, n = 12

    Only the combination showed an improvement in orthostatic tolerance, as indicated by a significantly higher AUCSBP (690±479) compared to that of each drug alone (placebo [AUCSBP 443±443; P=0.016], atomoxetine [AUCSBP 428±440; P=0.001] and yohimbine [AUCSBP 570±350; P=0.049])

    PMID 22311903 · one of two readings recorded this

  • orthostatic tolerance (AUCSBP)

    increases, p = 0.001, n = 12

    Only the combination showed an improvement in orthostatic tolerance, as indicated by a significantly higher AUCSBP (690±479) compared to that of each drug alone (placebo [AUCSBP 443±443; P=0.016], atomoxetine [AUCSBP 428±440; P=0.001] and yohimbine [AUCSBP 570±350; P=0.049])

    PMID 22311903 · one of two readings recorded this

  • orthostatic tolerance (AUCSBP)

    increases, p = 0.049, n = 12

    Only the combination showed an improvement in orthostatic tolerance, as indicated by a significantly higher AUCSBP (690±479) compared to that of each drug alone (placebo [AUCSBP 443±443; P=0.016], atomoxetine [AUCSBP 428±440; P=0.001] and yohimbine [AUCSBP 570±350; P=0.049])

    PMID 22311903 · one of two readings recorded this

  • plasma norepinephrine supine

    no effect, p = 0.792, n = 17

    Supine and upright plasma norepinephrine were similarly low in PAF and PD patients (supine, 100±85 vs. 78±46 pg/mL, P=0.792; upright, 186±216 vs. 121±53 pg/mL, P=0.673)

    PMID 22311903 · one of two readings recorded this

  • plasma norepinephrine upright

    no effect, p = 0.673, n = 17

    Supine and upright plasma norepinephrine were similarly low in PAF and PD patients (supine, 100±85 vs. 78±46 pg/mL, P=0.792; upright, 186±216 vs. 121±53 pg/mL, P=0.673)

    PMID 22311903 · one of two readings recorded this

  • seated SBP absolute value

    increases, n = 17

    with an average SBP of 129±38 mmHg

    PMID 22311903 · one of two readings recorded this

  • seated SBP at 60 minutes versus sum of individual drug effects

    increases, p = 0.024, n = 17

    We found that the combination had a higher seated SBP 60 minutes after drug administration compared to the sum of the pressor effects produced by the two drugs individually (P=0.024, Figure 2)

    PMID 22311903 · one of two readings recorded this

  • seated SBP at 60 minutes

    increases, p = 0.001, n = 17

    For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001])

    PMID 22311903 · one of two readings recorded this

  • seated SBP at 60 minutes

    increases, p = 0.001, n = 17

    For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001])

    PMID 22311903 · one of two readings recorded this

  • seated SBP at 60 minutes

    increases, p = 0.001, n = 17

    For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001])

    PMID 22311903 · one of two readings recorded this

  • seated SBP baseline

    no effect, p = 0.691, n = 17

    Average baseline seated SBP was similar among treatment groups (placebo 100±24 mmHg, yohimbine 103±25 mmHg, atomoxetine 99±25 mmHg and the combination 98±19 mmHg; P=0.691)

    PMID 22311903 · one of two readings recorded this

  • seated SBP

    no effect, p = 0.05, n = 17

    whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B)

    PMID 22311903 · one of two readings recorded this

  • seated SBP

    no effect, p = 0.05, n = 17

    whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B)

    PMID 22311903 · one of two readings recorded this

  • seated systolic blood pressure 60 minutes after a single oral dose of yohimbine 5.4 mg against placebo, by automated brachial cuff (Dinamap) every 5 minutes, in patients with severe peripheral autonomic failure

    no effect, seated SBP after yohimbine alone not different from placebo

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001]); whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B).

    PMID 22311903 · one of two readings recorded this

  • seated systolic blood pressure 60 minutes after a single oral yohimbine 5.4 mg dose vs placebo (Dinamap automated brachial cuff, baseline 30 min, seated, patients with peripheral autonomic failure); also orthostatic tolerance as AUC of standing SBP and a 6-item orthostatic symptom score. The yohimbine plus atomoxetine arm is a separate arm and is not the contrast recorded.

    no effect, SBP after yohimbine alone not different from placebo, n = 17

    Not recorded as a finding: a node exists but the paper states a different instrument or population

    For our primary outcome, we found that seated SBP was significantly higher 60 minutes after the combination than after each drug alone (placebo [P<0.001], atomoxetine [P<0.001] and yohimbine [P=0.001]); whereas the SBP after atomoxetine or yohimbine was not different from placebo (P> 0.05; Figure 1B).

    PMID 22311903 · one of two readings recorded this

  • total orthostatic symptom score adjusted for baseline

    no effect, p = 0.05

    the total symptom burden after atomoxetine or yohimbine alone were not significantly different from placebo (P> 0.05)

    PMID 22311903 · one of two readings recorded this

  • total orthostatic symptom score adjusted for baseline

    decreases, p = 0.022

    Only the combination showed a post-drug total symptom score significantly smaller than placebo after adjusting for the baseline total score (mean difference −11.1, 95% CI: −20.7 to −1.6; P = 0.022)

    PMID 22311903 · one of two readings recorded this

  • total orthostatic symptom score

    no effect, p = 0.799, n = 10

    In contrast, the total symptom burden did not improve after atomoxetine (24.4±18.3 vs. 26.9±14.1 at baseline; P=0.799) or yohimbine alone (26.4±12.9 vs. 27.6±12.2 at baseline; P=0.905)

    PMID 22311903 · one of two readings recorded this

  • total orthostatic symptom score

    decreases, p = 0.013, n = 10

    The total orthostatic symptom burden after 1 hour post-drug significantly improved with the combination (lower scores) as compared to baseline (15.7±17.9 vs. 25.3±16.0, respectively; P=0.013; Figure 4)

    PMID 22311903 · one of two readings recorded this

The whole record — 848 rows